Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Jan 2018 | FROM EXTERNAL EXPERTS

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

Estes, C. et al. Hepatology

May 2017 | FROM EXTERNAL EXPERTS

A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys

Stanislaus, S. et al. Endocrinology

Apr 2017 | FROM EXTERNAL EXPERTS

FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists

Li, X. et al. Journal of Bone and Mineral Research

Jan 2017 | From External Experts

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

Dulai, P et al Hepatology

Nov 2016 | FROM EXTERNAL EXPERTS

An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function

Lee, J.H. et al. American Journal of Translational Research

Sep 2016 | FROM EXTERNAL EXPERTS

Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-κB signaling pathway

Yu, Y. et al. International Immunopharmacology

Jan 2016 | FROM EXTERNAL EXPERTS

Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways

Xu, P. et al. Toxicology and Applied Pharmacology

Nov 2015 | FROM EXTERNAL EXPERTS

Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders

Zhang, H., Yang, L. Frontiers in Endocrinology

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.

View Our Pipeline

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.

View Our Pipeline